<DOC>
	<DOC>NCT01213641</DOC>
	<brief_summary>The purpose of this observational study is to collect additional information regarding long-term safety and effectiveness of Ilaris in the treatment of CAPS patients in clinical practice.</brief_summary>
	<brief_title>Clinical Outcomes and Safety: A Registry Study of Ilaris (Canakinumab) Patients</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Cryopyrin-Associated Periodic Syndromes</mesh_term>
	<criteria>Patients receiving Ilaris (canakinumab) at the time of enrollment as part of medical care Local regulations in some locations may exclude patients who receive Ilaris for a nonapproved indication Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Cryopyrin-associated periodic syndromes(CAPS)</keyword>
	<keyword>CIAS1 protein</keyword>
	<keyword>NLRP3 protein</keyword>
	<keyword>human cryopyrin protein</keyword>
	<keyword>Familial Cold Autoinflammatory Syndrome(FCAS)</keyword>
	<keyword>Muckle-Wells Syndrome(MWS)</keyword>
	<keyword>Neonatal Onset Multisystem Inflammatory disease(NOMID)</keyword>
	<keyword>NALP3</keyword>
	<keyword>canakinumab</keyword>
	<keyword>Interleukin-1(IL-1)</keyword>
</DOC>